|
|
||||||||
38)
Departments of 1 Biopharmaceutical Sciences, 2 Bioengineering, and 3 Medicine, University of Illinois at Chicago, and 4 Chicago Veterans Afffairs Health Care System, West Side Division, Chicago, Illinois 60612
The
purpose of this study was to elucidate the interactions between
pituitary adenylate cyclase-activating peptide (PACAP)-(1
38) and
phospholipids in vitro and to determine whether these phenomena modulate, in part, the vasorelaxant effects of the peptide in the
intact peripheral microcirculation. We found that the critical micellar
concentration of PACAP-(1
38) was 0.4-0.9 µM. PACAP-(1
38) significantly increased the surface tension of a
dipalmitoylphosphatidylcholine monolayer and underwent conformational
transition from predominantly random coil in saline to
-helix in
the presence of distearoyl-phosphatidylethanolamine-polyethylene glycol (molecular mass of 2,000 Da) sterically stabilized phospholipid micelles (SSM) (P < 0.05). Using intravital
microscopy, we found that aqueous PACAP-(1
38) evoked significant
concentration-dependent vasodilation in the intact hamster cheek pouch
that was significantly potentiated when PACAP-(1
38) was associated
with SSM (P < 0.05). The vasorelaxant effects
of aqueous PACAP-(1
38) were mediated predominantly by PACAP type 1 (PAC1) receptors, whereas those of PACAP-(1
38) in SSM
predominantly by PACAP/vasoactive intestinal peptide type 1 and 2 (VPAC1/VPAC2) receptors. Collectively,
these data indicate that PACAP-(1
38) self-associates and interacts avidly with phospholipids in vitro and that these phenomena amplify peptide vasoactivity in the intact peripheral microcirculation.
neuropeptide; amphipathic; micelles; distearoyl-phosphatidylethanolamine-polyethylene glycol; vasodilation; receptor antagonist; hamster
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |